A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

Author:

Lin Chia-Chi1,Garralda Elena2,Schöffski Patrick3,Hong David S.4,Siu Lillian L.5,Martin Miguel6,Maur Michela7,Hui Rina8,Soo Ross A9,Chiu Joanne10,Zhang Tian11,Ma Brigette12,Kyi Chrisann13,Tan Daniel SW14,Cassier Philippe A.15,Sarantopoulos John16,Weickhardt Andrew17,Carvajal Richard D.18,Spratlin Jennifer19,Esaki Taito20,Rolland Fréderic21,Akerley Wallace22,Deschler-Baier Barbara23,Rispoli Lawrence24,Samant Tanay S.25,Chowdhury Niladri Roy25,Gusenleitner Daniel24,Kwak Eunice L.24,Askoxylakis Vasileios24,De Braud Filippo26

Affiliation:

1. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

2. Vall d’Hebron Institute of Oncology (VHIO), Vall d´Hebron Hospital, Barcelona, Spain

3. Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium

4. Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas and MD Anderson Cancer Center, Houston, TX, USA

5. Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada

6. Gregorio Marañón Hospital, Universidad Complutense, Madrid, Spain

7. Oncology and Haematology Department, Università degli Studi di Modena e Reggio Emilia, Emilia-Romagna, Italy

8. Department of Medical Oncology, Westmead Hospital and the University of Sydney, Sydney, Australia

9. Department of Haematology-Oncology, National University Cancer Institute, Singapore

10. Department of Medicine, Queen Mary Hospital, Hong Kong, China

11. Department of Medicine, Duke Cancer Institute, Durham, NC, USA

12. Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China

13. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

14. National Cancer Centre, Singapore and Duke-NUS Medical School, Singapore

15. Department of Medical Oncology, Centre Léon Bérard, Lyon, France

16. Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA

17. Medical Oncology Dept, Olivia Newton-John Cancer Centre, Austin Health, Melbourne, Victoria, Australia

18. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA

19. Cross Cancer Institute, University of Alberta, Edmonton, Canada

20. Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

21. Department of Medical Oncology, Institut de Cancérologie de l’Ouest – Centre René Gauducheau, Nantes, France

22. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

23. Translational Oncology, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany

24. Novartis Institutes for BioMedical Research, Cambridge, MA, USA

25. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

26. Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy and Oncology and Hemato-oncology Department, University of Milan, Milan, Italy

Funder

This study was sponsored by Novartis Pharmaceuticals Corporation

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3